For investors
Menu
For investors

Leo Cancer Care, Raysearch Laboratories and Terapet Bring Real-Time In Vivo Treatment Verification to Particle Therapy

Leo Cancer Care and Terapet Bring Real-Time In Vivo Treatment Verification to Particle Therapy Collaboration to integrate PET-based verification technology within the Marie® system, enhancing precision and confidence in cancer treatment delivery  CRAWLEY, UNITED KINGDOM & GENEVA, SWITZERLAND – 16 MAY 2026 – The collaboration between Leo Cancer Care and Terapet aims to offer advanced treatment verification capabilities, bringing real-time, patient-specific treatment validation […]

Heidelberg Ion-Beam Therapy Center, University of Applied Sciences Giessen, EQ Photonics GmbH and Terapet SA Launch FLASHVIVO to Enable In-Beam PET Verification and Biological Guidance in FLASH Particle Therapy

Geneva, Switzerland, March 2026 – Terapet SA announces the launch of FLASHVIVO – Biological Guidance and In Vivo PET Verification in FLASH Particle Therapy, a new collaborative R&D project aimed at addressing one of the key barriers to the clinical adoption of FLASH therapy: the lack of real-time, in-vivo verification under ultra-high dose rate conditions. […]

Terapet SA, RaySearch Laboratories AB, Uppsala University and Skandion Clinic Secure Eurostars Funding to Advance In-Vivo Verification and Adaptive Proton Therapy

Geneva, Switzerland, January 2026 – Terapet SA, a Geneva-based MedTech spin-off from CERN developing advanced medical imaging technologies for nuclear medicine and particle therapy, announces the award of a new Eurostars grant supporting its latest innovation project, TheraVivo – Establishing State-of-the-Art Standards for In-Vivo Verification and Adaptive Treatment Planning in Proton Therapy. The TheraVivo project […]

TERAPET expands into South Korea through strategic partnership with MediinHealthcare

Geneva, Switzerland – 9 February 2026  TERAPET SA has entered into a new strategic partnership with MediinHealthcare Co., Ltd., an established provider of advanced medical technologies with strong expertise in radiation oncology and particle therapy in South Korea. Under this agreement, MediinHealthcare will serve as TERAPET’s official distributor in South Korea, supporting clinical sites through local commercial activities […]

TERAPET announces strategic distribution partnership with Anzai Medical in Japan 

Geneva, Switzerland – 26 January 2026  We are pleased to announce a new strategic partnership with Anzai Medical Co., Ltd., a leading provider of advanced medical technologies in Japan.  Under this agreement, Anzai Medical will serve as TERAPET’s exclusive distributor in Japan, supporting the introduction and adoption of TERAPET’s flagship platform Qualyscan® in clinical particle therapy workflows at leading centers of excellence nationwide.  This collaboration represents an important milestone in TERAPET’s international growth strategy and reinforces the company’s mission to make particle therapy safer, smarter, and more adaptive through imaging-driven verification. Qualyscan® enables end-to-end verification of particle beam delivery by combining […]

Terapet achieves ISO 13485:2016 certification

We are proud to announce that we have officially achieved ISO 13485:2016 certification for our Quality Management System. The ISO 13485:2016 standard is the internationally recognized benchmark for quality management systems in the medical device industry. It sets out the requirements that organizations must meet to consistently deliver safe and effective medical devices. This certification […]

Terapet successfully completes pre-clinical testing of heavy particle therapy device

We at Terapet are thrilled to announce the successful completion of preclinical testing for our innovative Qualγscan heavy particle therapy device. This achievement was made possible through our collaboration with Yonsei Cancer Hospital and Oncosoft. The preclinical tests, conducted at Yonsei Cancer Hospital—the first in Korea to pioneer autonomous heavy particle therapy—highlight the potential of […]

CERN Highlights 2023: Explore how CERN accelerates innovation

At Terapet SA, we are pleased to highlight our successful partnership with CERN, a collaboration that propelled us to the forefront of cancer treatment innovation. Together with our world-class partners, we successfully developed Qualyscan, the world’s first end-to-end quality assurance device for proton and heavy ion therapy. With the support of external funding for the […]

Eurostars grant to develop a cutting-edge PET scanner

Today, we proudly announce the receipt of a non-dilutive grant totaling approximately EUR 1.68 million from the European Commission through the Eurostars Program. This remarkable milestone has been made possible through the collaborative efforts of Terapet SA, alongside our esteemed partners: Inselspital Department of Nuclear Medicine from Switzerland, Politecnico di Milano, and Nuclear Instruments from […]